Company: MIRA
Filing Date: 2025-07-29
Form Type: PRER14A
Source: 0001641172-25-021434
Chunk: 213

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-07-29
Form: PRER14A
Chunk 213
---
 of the hippocampus, a region critical for memory processing |

| ■ | Enlarged                                                         
 brain ventricles, the fluid-filled spaces that cushion the brain |

| ■ | Reduced                                                                                      
 glucose metabolism in specific brain regions, indicating lower activity in areas responsible 
 for memory and thinking                                                                      |

These findings support the understanding of MCI as a complex, multifactorial condition, with both degenerative and vascular components potentially contributing to its development.

Complications of mild cognitive impairment include a higher risk — but not a certainty — of dementia. Overall, about 1% to 3% of older adults develop dementia every year. Studies suggest that around 10% to 15% of people with mild cognitive impairment go on to develop dementia each year 4.

Diagnosis of MCI

There is no single test that can definitively diagnose Mild Cognitive Impairment (MCI). Instead, the diagnosis is made through a comprehensive evaluation that includes medical history, clinical assessment, and cognitive testing. Most healthcare providers follow internationally recognized criteria established by expert panels. These include:

| ■ | Noticeable                                                                                   
 cognitive changes: Individuals with MCI often report issues with memory, planning, following 
 instructions, or making decisions. These concerns are typically confirmed by someone close   
 to the individual, such as a family member or friend.                                        |

4https://www.mayoclinic.org/diseases-conditions/mild-cognitive-impairment/symptoms-causes/syc-20354578

| Moore Financial Consulting |

| MIRA Pharmaceuticals, Inc. | April 2025    |
| Valuation                  | Page 14 of 28 |

| ■ | Documented                                                                                      
 decline over time: A detailed medical history helps establish that cognitive ability            
 has declined from a previous baseline. Input from close contacts helps verify this progression. |

| ■ | Preserved                                                                                    
 daily functioning: Although cognitive changes are present, individuals with MCI can continue 
 to perform daily activities independently. The condition does not interfere with routine     
 life at home or work.                                                                        |

| ■ | Mild                                                                                              
 impairment shown on cognitive tests: Standardized screening tools — such as the                   
 Short Test of Mental Status, the Montreal Cognitive Assessment (MoCA), or the Mini-Mental         
 State Examination (MMSE), may reveal subtle deficits appropriate to age and education level.      
 More comprehensive neuropsychological testing can help determine the extent and type of cognitive 
 impairment.                                                                                       |

| ■ | Does                                                                                     
 not meet criteria for dementia: While M